Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small... see more

Recent & Breaking News (NDAQ:ACIU)

AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome

GlobeNewswire August 20, 2018

AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update

GlobeNewswire August 8, 2018

AC Immune Announces Successful Closing of Second Subscription Rights Offering

GlobeNewswire July 31, 2018

New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong Evidence for Engagement of the Principle Abeta Target

GlobeNewswire July 25, 2018

AC Immune Announces Closing of First Subscription Rights Offering and Primary Offering as well as Full Exercise of Option to Purchase Additional Shares

GlobeNewswire July 23, 2018

AC Immune Announces Offerings and Issuance of up to 10 Million Common Shares

GlobeNewswire July 17, 2018

Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago

GlobeNewswire July 17, 2018

AC Immune Announces Results of Annual General Meeting

GlobeNewswire July 6, 2018

Research Report Identifies AC Immune SA, Vipshop, Infosys, STMicroelectronics N.V., BRF S.A., and National Steel with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire June 8, 2018

AC Immune Reports First Quarter 2018 Financial Results and Corporate Update

GlobeNewswire May 2, 2018

AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease

GlobeNewswire April 5, 2018

AC Immune reports full-year 2017 financial results - successful first year as a public company

GlobeNewswire March 20, 2018

AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease

GlobeNewswire March 15, 2018

The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Benzinga.com  February 8, 2018

AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference

GlobeNewswire February 6, 2018

AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

GlobeNewswire December 1, 2017

AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

GlobeNewswire November 21, 2017

AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update

GlobeNewswire November 13, 2017

AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease

GlobeNewswire November 2, 2017

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference

GlobeNewswire October 24, 2017